Decrease in Newly Diagnosed Breast Cancer Seen in First Year of Pandemic
By Elana Gotkine HealthDay Reporter
FRIDAY, March 29, 2024 -- There was a reduction in the number of newly diagnosed breast cancer cases from 2019 to 2020, according to a study published in the January issue of Cancer Medicine.
Marie Fefferman, M.D., from the NorthShore University Health System in Evanston, Illinois, and colleagues examined the incidence of breast cancer cases at Commission on Cancer sites to examine the impact of the early part of the COVID-19 pandemic on the number of newly diagnosed breast cancer cases. Data were included for 1,499,806 patients with breast cancer.
The researchers found that breast cancer cases per 100,000 individuals increased from 188 in 2015 to 203 in 2019, then decreased to 176 in 2020 (15.7 percent decrease) for women. For men, breast cancer cases per 100,000 increased from 1.7 in 2015 to 1.8 in 2019, then decreased to 1.5 in 2020 (21.8 percent decrease). For almost all age groups, cases per 100,000 individuals decreased from 2019 to 2020 for both men and women. For all races and ethnicities and geographic locations, rates declined from 2019 to 2020 for women. The largest percentage change was seen for Hispanic patients and those in the Middle Atlantic division (−18.4 and −18.6 percent, respectively). From 2018 to 2020, the stage distribution remained stable for female and male patients.
"Future research is needed to determine when case numbers will return to baseline levels and what the consequences will be of delayed diagnosis and care, particularly among patients and geographic areas that were most severely affected by the pandemic," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Further Support and Information on COVID-19
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.